Rallybio Corporation (RLYB) Max Pain Analysis
Max pain is the strike price where aggregate option buyer payout is minimized at expiration. It represents the price at which option writers retain the most premium.
Rallybio Corporation (RLYB) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $77.0M, listed on NASDAQ, employing roughly 15 people, carrying a beta of -1.10 to the broader market. Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Led by Stephen Uden, public since 2021-07-29.
Max pain analysis shows the strike price where the most options expire worthless. No recent options activity for RLYB as of 2026-06-02; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.